天美传媒

Dr. Angela Alistar is a board-certified medical oncologist with Atlantic Hematology Oncology, Atlantic Medical Group.  Dr. Alistar is Medical Director of GI Medical Oncology at Morristown Medical Center where she is also Medical Director of the Phase 1 Breakthrough Treatment Center.  Her research focus is related to immuno-oncology and cancer metabolism in gastrointestinal cancer such as: pancreatic tumors, cholangiocarcinoma, colorectal, esophageal, gastric cancer and hepatocellular carcinoma. Her clinical research projects involved active collaborative efforts with other medical departments, such as radiation oncology and surgical oncology, as well as genomics and cancer biology.

Recently, she has published in Lancet Oncology the results of a Phase 1 clinical study in pancreatic cancer that are very promising for advancing the field for this disease. This study has shown impressive synergy of a novel agent, CPI -613 in combination with chemotherapy. She is co-leading the national multi-site, randomized study of this promising combination, as well as many other phase 1-3 clinical trials.

Dr. Alistar comes to Atlantic Health System from Wake Forest School of Medicine where she had a heavy emphasis on clinical trials and clinical research. At Wake Forest, she led the GI oncology disease oriented team as a gastrointestinal medical oncology physician and researcher, bringing cutting-edge treatments to patients. She designed, secured funding for and conducted five investigator-initiated therapeutic clinical trials, with four of them being phase one. Her work involved maintenance of a sponsor-investigator investigational new drug. She is passionate about Precision Oncology and Immunotherapies and seeks to identify novel treatment strategies for her patients.

Past positions at Wake Forest include being a member of the Translational Cancer Genomics Committee, the GI Tumor Board, Internal Medicine Grand Rounds, and the Hepatobiliary Oncology Committee. She is a member of several health care organizations, such as the American Society of Clinical Oncology, the American Society of Hospice and Palliative Care Medicine, and the American Society of Hematology, among many others. As well, she is a member and advisor for several other health care institutions. She was recently awarded the "Danny Danielson Translational Innovation Award" by Hoosier Cancer Research Network for her commitment to clinical research. 

She received her medical degree from University of Medicine and Pharmacy, Cluj Napoca, Romania and her residency at Englewood Hospital and Medical Center, NJ, where she was chief resident. After her residency, she completed a hematology oncology fellowship at Mount Sinai School of Medicine, Tisch Cancer Institute. She is affiliated with Atlantic Medical Group, and is a participating provider of Atlantic Accountable Care Organization, and sees patients at Morristown Medical Center.

Weijing Sun, MD, FACP, is a Director of Division of Medical Oncology in University of Kansas School of Medicine, and an Associate Director of University of Kansas Cancer Center. He specializes in the treatment of colorectal cancer.

Dr. Sun is board-certified in internal medicine and medical oncology. He received his medical degree from Shanghai Medical College, Fudan University, in Shanghai. He completed his residency in internal medicine at Loyola University Medical Center in Maywood, Ill., and his hematology-oncology fellowship at the University of Pennsylvania in Philadelphia.

Dr. Sun is a member of the American Medical Association, the American Society of Clinical Oncology, the American Association of Cancer Research, the Eastern Cooperative Group of Oncology Gastrointestinal Cancer Core Committee, the American College of Physicians 鈥� Internal Medicine, the NCI Gastrointestinal Cancer Steering Committee Hepatobiliary Task Force, and serves on the American Society of Clinical Oncology Scientific Program and Membership Committee. In addition, Dr. Sun has been recognized on U.S. News & World Report鈥檚 American Top Doctors list.

Steven K. Libutti, MD, FACS, was appointed as Director of Rutgers Cancer Institute of New Jersey and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences in January 2017. In addition to his leadership roles within Rutgers University, Dr. Libutti also serves as Senior Vice President of Oncology Services for RWJBarnabas Health, further strengthening the university鈥檚 partnership with the healthcare system. He is also a Professor of Surgery at Rutgers Robert Wood Johnson Medical School and an Affiliated Distinguished Professor in Genetics at the Rutgers School of Arts and Sciences Department of Genetics.

Most recently, Dr. Libutti served as Director for the Montefiore Einstein Center for Cancer Care in New York City and was a Professor and Vice Chairman of the Department of Surgery and Professor in the Department of Genetics at Albert Einstein College of Medicine and Montefiore Health System. A surgical oncologist, Dr. Libutti is an internationally known expert in endocrine surgery and the management of neuroendocrine tumors. He is the immediate Past President of the American Association of Endocrine Surgeons. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas.

The recipient of funding from the National Cancer Institute (NCI) for the past 20 years, Dr. Libutti is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment and blood vessel formation in tumors. He is studying tumor neovascular formation and the interaction between tumor cells, endothelial cells and the components of the tumor microenvironment including fibroblasts and cancer stem cells. His work also focuses on a better understanding of the tumor suppressor genes MEN1 and FILIP1L.

After graduating magna cum laude from Harvard College, Dr. Libutti received his medical degree from the College of Physicians and Surgeons of Columbia University. He remained at Presbyterian Hospital in New York where he completed his residency in surgery, followed by a fellowship at the NCI in surgical oncology and endocrine surgery. He continued at the NCI where he became a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch.  He has published over 280 peer reviewed journal articles, is Editor-in-Chief of the Nature Journal Cancer Gene Therapy, and holds seven U.S. patents. 

Clinical Expertise:
Neuroendocrine tumors, thyroid cancer, parathyroid tumors, pancreatic cancer, liver cancer, gastrointestinal (GI) cancers, minimally invasive surgery, and clinical trials.

Cosimo Commisso, Ph.D., studies pancreatic cancer, one of the deadliest cancers. He is particularly interested in how the tumor gets nutrients from its environment, as cutting this fuel supply could stop the cancer鈥檚 growth.

Debashish Bose, M.D., PhD, FACS, an experienced, well-respected surgeon, serves as Medical Director of The Center for Hepatobiliary Disease at Mercy as well as Associate Director of Surgical Oncology at Mercy in Baltimore, Maryland. He is Board Certified in General Surgery and offers particular expertise in advanced surgical techniques for pancreatic cancer and liver cancer.

Dr. Bose provides leading edge cancer treatment options, including minimally invasive and robotic surgery in the care of late-stage and complex oncologic disease. He and his colleagues treat benign and malignant tumors in the peritoneal and abdominal cavity, including:

路         Stomach and Gastrointestinal Tract Tumors and Cancer

路         Pancreatic and Neuroendocrine Tumors

路         Soft Tissue Sarcoma

路         Metastatic Colon Cancer

路         Liver Tumors

路         Adrenal Gland Cancer

Dr. Bose works in close collaboration with the liver and pancreatic experts at Mercy鈥檚 Institute for Digestive Health and Liver Disease to provide patients the best possible outcome for their diagnosis.

Mercy Medical Center鈥檚 renowned surgical oncologists teamed with the experience of its liver and pancreatic experts provide patients seeking care for pancreatic cancer one of the most comprehensive gastrointestinal cancer teams in the Mid-Atlantic region.

In addition to offering surgical expertise, Dr. Bose aims to provide cancer patients with the knowledge and information needed for them to better understand their specific diagnosis, treatment and outcomes. He has dedicated his career to becoming an ally and a resource for patients facing late-stage and complex cancers. He guides patients through the treatment process and helps them make decisions to optimize their care and regain hope for a better quality of life.

Second opinion consultation and collaborative care with partner physicians make Dr. Bose a trusted expert among both patients and colleagues. Gastroenterologists, medical oncologists and primary care physicians rely on Dr. Bose for his insights, surgical skill and commitment to improving cancer survival.

Dr. Debashish Bose actively participates in research and has been the recipient of the Ruth L. Kirschstein National Research Service Award (NRSA). He has served as Principle Investigator in studies related to pancreatic cancer. His work has been published in peer-reviewed articles, book chapters and abstracts, and he has made numerous presentations to foster clinical advances in surgical oncology.

Education & Fellowships

路         Fellowship: University of Texas MD Anderson Cancer Center

路         Residency: Johns Hopkins Hospital

路         Medical Degree: University of Maryland School of Medicine

Michael Cecchini, MD, is a medical oncologist who specializes in gastrointestinal cancers, including (but not limited to) colorectal, bile duct, pancreas, esophageal, and stomach cancers. He often cares for patients with advanced gastrointestinal cancers and is an investigator in multiple research trials to help them get treatments that are not always available elsewhere.
“Taking care of patients and spending the time to get to know them is the best part of my job,” Dr. Cecchini says. It helps to draw upon the diverse expertise of colleagues at Smilow and those in non-cancer specialties, he adds. “At Yale we have an excellent multidisciplinary team that will work hard to treat your cancer, manage your symptoms, and deliver the care you deserve as a patient.”
Dr. Cecchini was inspired to become a cancer specialist partly because he wanted to have opportunities to perform research to improve options for his patients. “Few specialties are so integrated with close patient relationships and translational research that can dramatically improve the lives of our patients and minimize side effects,” he says. His translational research includes clinical and lab projects to study DNA damage and the immune response, primarily for colorectal cancer. He is the recipient of a Young Investigator Award from the Conquer Cancer Foundation for research focused on metastatic gastric cancer and 2020 Scholar on the Yale Cancer Center K12 Calabresi Immuno-Oncology Training Program.

, is the director of Moores Cancer Center at UC San Diego Health. She provides the overall strategic and intellectual direction for the center’s research programs, administrative structure, and multidisciplinary cancer clinical care. She serves as the principal investigator for the Cancer Center’s support grant sponsored by the National Cancer Institute (NCI).
Simeone, a , partners with academic and clinical leaders to guide cancer research and care and provides counsel to campus and university-level committees. She manages day-to-day operations, including scientific, education, and clinical programs.
Prior to her current role, Simeone served as the director of the Pancreatic Cancer Center and was the associate director of translational research at Perlmutter Cancer Center at New York University Langone Health. She is an internationally renowned pancreatic surgeon and researcher with a long-standing career focused on treating pancreatic cancer and pancreatic cystic tumors. Throughout her career, she has driven innovation in cancer care by building a continuum between scientific discovery and new approaches for cancer detection and treatment. She has published more than 230 studies in leading peer-reviewed journals.
Simeone served as the chair of the scientific and medical advisory board of the Pancreatic Cancer Action Network and is a past president of the American Pancreatic Association and Society of University Surgeons. She is an elected member of the National Academy of Medicine and is a member of the National Cancer Institute (NCI) Pancreatic Cancer Task force and the NCI Cancer Centers Study Section. She also serves on the Board of Directors for the National Comprehensive Cancer Network.
She is the principal investigator and lead of Precision Promise, a national clinical trials consortium focused on next-generation clinical trials for people with pancreatic cancer. She is also the founder of the Pancreatic Cancer Early Detection (PRECEDE) Consortium, an international consortium established to drive the early detection of pancreatic cancer.